Navigation Links
Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
Date:9/27/2007

SOUTH SAN FRANCISCO, Calif., Sept. 27 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that the Company's common shares are now eligible to be included in the NASDAQ Global Market and will begin trading there under the same symbol "PARD" effective Monday, October 1, 2007.

"Qualifying for listing on the NASDAQ Global Market represents an important milestone for Poniard and provides us with greater visibility in the global financial markets and broadens our exposure to new investors," said Caroline Loewy, chief financial officer of Poniard. "This is an important step in our continued growth and demonstrates our ability to meet the higher standards required by the NASDAQ Global Market."

NASDAQ-listed companies are classified under three listing tiers -- NASDAQ Global Select Market, NASDAQ Global Market and NASDAQ Capital Market. Poniard has been listed on the NASDAQ Capital Market. All three market tiers maintain rigorous listing and corporate governance standards. For additional information about the NASDAQ Global Market, please visit http://www.nasdaq.com.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead product candidate, is a new generation platinum therapy with an improved safety profile. Picoplatin is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors. Intravenous picoplatin is currently being studied in clinical trials for the treatment of small cell lung, colorectal and hormone-refractory prostate cancer, and oral picoplatin is in a clinical trial in solid tumors. As part of the Company's strategic goal of building a diverse oncology pipeline, the Company is collaborating with The Scripps Research Institute on the discovery of novel, small-molecule, multi-targeted protein kinase inhibitors. For additional information please visit http://www.poniard.com.

(C) 2007 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2020)... ... January 07, 2020 , ... ... and services, today announced the launch of its VivopureX™ recombinant mouse antibodies for ... many originally obtained from rats or hamsters, which Absolute Antibody has engineered into ...
(Date:12/31/2019)... ... December 31, 2019 , ... Vici Health ... development lab in Maryland. Emphasis will be in expanding capabilities in both ... Health Sciences will be well positioned to meet the growing demand for its ...
(Date:12/23/2019)... ... December 23, 2019 , ... Leak Detection Associates, the leading ... Medical Device Industries, is excited to announce that it will be a contributing ... Closure Integrity Testing Basic Training Course . Held in conjunction with PDA Europe’s ...
(Date:12/6/2019)... ... December 06, 2019 , ... ... Medcure, Inc. has received FDA 510(k) clearance for its latest CAPERE® Thrombectomy ... clinical data suggests the CAPERE® offers great benefits for first-in-line treatment for ...
Breaking Biology Technology:
(Date:12/2/2019)... ... December 01, 2019 , ... Each year ... and techniques to hit the life-science landscape. For more than a decade, our ... in laboratories and facilitating biological discovery. This year’s crop of entries to The ...
(Date:11/27/2019)... ... November 26, 2019 , ... Personalized Stem Cells, Inc ... by the Arthritis Foundation and hosted by Dr. Steven Sampson and Dr. Danielle Aufiero ... place on October 23, 2019, highlighted the ongoing efforts to promote research, educate the ...
(Date:11/20/2019)... (PRWEB) , ... November 20, 2019 , ... BioInformatics Inc., ... life science tools market, today announced the winners of the Life Science Industry Awards ... of the Life Science Industry Awards – Innovation: , Most Innovative New Product – ...
Breaking Biology News(10 mins):